Navigation Links
Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
Date:3/6/2008

nticipated filing a supplemental New Drug Application for Renvela's use in non-dialysis patients during the first half of 2008. Given the current discussions with the FDA, it will not be necessary for the company to file an sNDA for this indication. However, Genzyme anticipates the Renvela label expansion will take place within a similar timeframe had it gone a more traditional route. During the second quarter, Genzyme also plans to file for U.S. approval of the powder formulation of the product, which may make it easier for patients to comply with their prescribed treatment program.

"We are very pleased with the progress we've made to date on our comprehensive global plan for Renvela," stated John P. Butler, president, Genzyme Renal. "The U.S. launch in dialysis, the E.U. and Brazil filings, and the positive nature of our current conversations with the FDA represent significant steps forward as we work to make this important product available to all patients who can benefit from it."

Renvela is a next-generation version of Renagel(R) (sevelamer hydrochloride), the most-prescribed phosphate binder in the United States. It is a calcium-free, metal-free, non-absorbed phosphate binder and is available in the U.S. as 800mg tablets. Renvela offers all of the advantages of Renagel with the benefit of a carbonate buffer. In a clinical study comparing Renvela to Renagel, both drugs controlled serum phosphorus equally to within KDOQI recommended ranges. Patients on Renvela, however, were more likely to maintain bicarbonate levels within the recommended KDOQI ranges, and had a lower incidence of gastrointestinal adverse events.

About Renagel and Renvela

Renagel (sevelamer hydrochloride) and Renvela (sevelamer carbonate) both control serum phosphorus in patients with chronic kidney disease (CKD) on dialysis. Controlling serum phosphorus is an important element in the care of dialysis patients. Elevated serum phosphorus levels are common in dialysis
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
2. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
3. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
4. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
5. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
6. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
7. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
8. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
9. Genzyme Launches Cholestagel(R) in Europe
10. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
11. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 The largest international professional organization ... and therapeutic derivatives thereof has endorsed an educational ... about the challenges of adulterated herb and botanical ... The Society for Medicinal Plant and ...
(Date:1/14/2014)... 14, 2014 In recent years, growing ... methods in product development and promotion has led to ... mistrust, fueled by concerns about the insidious impact of ... of spectacular fines to the world’s biggest pharmas for ...
(Date:1/14/2014)... 2014   Kinaxis ®, provider of RapidResponse ®, a ... operations planning ( S&OP ) service, is proud to be ... will be held at the Hilton San Diego Bayfront, January ... Elisabeth Kaszas , Director of Supply Chain at Amgen, ...
(Date:1/14/2014)... During the 1600’s through the 1800’s doctors contributed ... In this time period, doctors did not know that they ... the death of vulnerable patients. In the same way, medical ... be unwittingly transmitting herpes viruses to their patients. The CBCD ...
Breaking Biology Technology:World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... May 19 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ... Quill(TM) SRS wound closure product line is now available ... at https://ecommerce.angiotech.com/Main/Home.aspx . The Quill SRS products are ... Polydioxanone (PDO), MONODERM(TM), Nylon and Polypropylene product lines. , ...
... with Novel Mode of ActionMOUNTAIN VIEW, Calif., May ... that data from the company,s PROTECT-1 (the Prospective ... Phase II/III clinical trial of Traficet-EN(TM) (CCX282-B) in ... in an oral session at the upcoming 2009 ...
... -- Leading pharmaceutical and biotech,companies are drawing on ... enhance their R&D productivity, leverage academic,insights and diversify ... a population,base that is representative of key Asian ... companies to test and develop new solutions for,Asia ...
Cached Biology Technology:Angiotech launches e-commerce website that allows customers to order Quill(TM) SRS product line 2Angiotech launches e-commerce website that allows customers to order Quill(TM) SRS product line 3Angiotech launches e-commerce website that allows customers to order Quill(TM) SRS product line 4ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 2ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 3ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 4ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 5Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 2Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 3Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 4Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 5
(Date:4/24/2014)... Allan, PhD, a scientist at Western University and the ... spreads or metastasizes to the lung. , Breast cancer ... two cause of cancer-related deaths among women in North ... have a high success rate, but once the disease ... particular, the lung is one of the most common ...
(Date:4/24/2014)... at Ludwig-Maximilians-Universitaet (LMU) in Munich have identified the ... to discriminate between viral and endogenous RNAs in ... take control of cellular metabolism and hijack cellular ... process is dependent on viral RNA molecules that ... RNA viruses) and/or newly synthesized in the host ...
(Date:4/24/2014)... be improved with new insights into the make-up of ... the Amazon Basin have revealed unprecedented detail of the ... by comparing satellite maps with hundreds of field plots. ... more accurately the amount of carbon each tree can ... schemes, in which trees are given a cash value ...
Breaking Biology News(10 mins):New study helps to explain why breast cancer often spreads to the lung 2Viral infections: Identifying the tell-tale patterns 2Viral infections: Identifying the tell-tale patterns 3Amazon rainforest survey could improve carbon offset schemes 2
... states are invited to attend the annual meeting of ... Oct. 28 and 29 in Spokane, Wash. The ... policy and technology of carbon capture and storage (CCS). ... carbon sequestration technologies, the economics of CCS, regulatory and ...
... Zeitlinger, Ph.D., Stowers Institute Assistant Investigator, has been ... National Institutes of Health (NIH). Dr. Zeitlinger was ... million over five years. The awards enable recipients ... biomedical and behavioral science. "Nothing is ...
... assistant bioengineering professor at the UC San Diego Jacobs School ... tissue engineering. With a new $1.5 million New Innovator Award ... be able to do just that. , The awards, ... small number of new investigators who have exceptional creativity and ...
Cached Biology News:Julia Zeitlinger selected for NIH Director's New Innovator Award 2Generation innovation: Young UC San Diego bioengineer to use NIH grant to fuel tissue engineering 2Generation innovation: Young UC San Diego bioengineer to use NIH grant to fuel tissue engineering 3
... Immunogen KLH-conjugated, synthetic ... 54-75 (RRGPHRNPG-PGDDDGQRSRSSS) of mouse p19ARF. ... to amino acids 62-75. Clone ... Routinely evaluated by immunoblot. ...
Request Info...
Hybridization cassette for one slide...
Request Info...
Biology Products: